Centene reaffirmed full-year 2026 GAAP diluted EPS guidance above $3.11 and adjusted diluted EPS guidance above $4.80. The benchmarks set the Earnings measures management will discuss with investors during the Deutsche Bank 2026 Healthcare Summit and subsequent meetings through the week of September 21.

Key Highlights

  • Management discussions with investors will continue through the week of September 21.
  • The 2026 guidance remains effective through September 25 unless Centene publicly updates or reaffirms it.
  • Centene’s full-year 2026 GAAP diluted EPS guidance is greater than $3.11, and adjusted diluted EPS guidance is greater than $4.80.

CENTENE CORP (NYSE: CNC) said management will discuss reaffirming full-year 2026 GAAP Diluted Earnings per Share guidance above $3.11 and adjusted diluted EPS guidance above $4.80.

$3.11 GAAP and $4.80 Adjusted EPS Guidance

The company said it uses non-GAAP measures internally to evaluate performance, plan operations and determine employee incentive compensation. A reconciliation between GAAP diluted EPS and adjusted diluted EPS is available in a press release dated July 28.

Guidance Remains Effective Through September 25

The guidance applies through September 25 and will not be updated or reaffirmed unless Centene publicly announces updated or affirmed guidance. Centene described the 2026 outlook as forward-looking and cautioned that actual results may differ because of economic, regulatory, competitive and other factors. Management discussions with investors continue through the week of September 21, while a live audio webcast will accompany the healthcare summit and a replay will be available afterward through Centene’s investor website.